1 Trending: WaPo Admits Many Democrat Voters Can’t Prove They’re Citizens

2 Trending: 3 Clever Ways To Pass The SAVE America Act If Republicans Keep Stonewalling

3 Trending: ‘Another Racial Gerrymander Bites The Dust’: DeSantis Approves New Florida Map Ahead Of Midterms

4 Trending: Health Care Would Improve If More States Eliminated Hospital ‘Permission Slips’

Abortion Drug Makers Admit They Care About Money, Not Women

The court ruled mifepristone makers’ ‘potential financial losses pale beside … interest in not exposing women to unsafe medical procedures.’

Share Article on Facebook

Share Article on Twitter

Share Article on Truth Social

Share Article via Email

The company responsible for manufacturing the most popular abortion pill on the market are more concerned about its profits than the harm its drugs are inflicting on women and babies.

The confession from mifepristone maker Danco Laboratories came in its defense against Louisiana’s landmark lawsuit targeting the U.S. Food and Drug Administration’s “mail-order abortion scheme.” The 5th Circuit Court of Appeals unanimously granted Louisiana’s request for a stay, effectively pausing the FDA’s mail-order abortion drug permissions. While the U.S. Supreme Court temporarily halted the 5th Circuit’s block just two days until both parties can brief the court, the case is considered ongoing.

Tucked in the 5th Circuit Court of Appeals’ ruling on Friday are Danco’s suggestions that its “substantial financial interest” in selling abortion drugs should outweigh Louisiana’s claims that mail-order abortion pills pose a danger to women and babies. The abortion pill manufacturers’ concerns about “compliance costs and mifepristone profits,” however, pale in comparison to the financial and physical harm that the 5th Circuit agreed Louisiana and abortion pill poisoning survivor Rosalie Markezich demonstrated in their lawsuit.

“Louisiana argues the district court erred by finding its irreparable harms are outweighed by FDA’s interest in continuing its review and Danco’s financial interests in selling mifepristone. We agree,” the 5th Circuit panel wrote.

For Louisiana to successfully secure a stay, the state had to demonstrate it was “irreparably........

© The Federalist